[問卦] 美國國家衛生院對伊維菌素治療段落翻譯

Prevention and Prophylaxis of SARS-CoV-2 Infection
摘自美國國家衛生院新冠肺炎治療指引2021/4/21文章

原文連結
https://www.covid19treatmentguidelines.nih.gov/overview/prevention-of-sars-cov-2/

文章結尾後段翻譯

Ivermectin伊維菌素

High concentrations of ivermectin have been shown to inhibit SARS-CoV-2
replication in vitro.20,21
高濃度的伊維菌素曾在實驗中展示有限制新冠病毒複製的能力

Population data also indicate that country-wide mass use of prophylactic
chemotherapy for parasitic infections, including the use of ivermectin, is
associated with a lower incidence of COVID-19.22
人口統計的資料顯示許多國家投放寄生蟲藥物(含有伊維菌素)很可能與降低新冠發病率有連結

At this time, there are limited clinical trials regarding the safety and
efficacy of ivermectin for SARS-CoV-2 PrEP or PEP. Although several studies
have reported potentially promising results, the findings are limited by the
design of the studies, their small sample sizes, and lack of details
regarding the safety and efficacy of ivermectin. The results of these trials
are described below.
這個時候，有少數的臨床試驗顯示伊維菌素可以做為新冠肺炎的預防用藥，即使有少數的研究顯示伊維菌速表現理想的結果，但這些研究樣本數較少，以及缺少伊維菌素有效、安全性的實驗細節，這些試驗的結果敘述如下

In a descriptive, uncontrolled interventional study of 33 contacts of
patients with laboratory-confirmed COVID-19, no cases of SARS-CoV-2 infectionwere identified within 21 days of initiating ivermectin for PEP.23
一項沒有控制組介入的研究敘述，33名確診者，在初期投藥(伊維菌素)後21天，沒有發現新冠感染

An open-label, randomized controlled trial investigated ivermectin
prophylaxis (plus personal protective measures [PPMs]) in health care workers(as PrEP) or in household contacts (as PEP) exposed to patients with
laboratory-confirmed COVID-19. The incidence of SARS-CoV-2 infection was
lower among the participants who received ivermectin than among control
participants who used only PPMs.
在一項開放式試驗，隨機控制研究中，以伊維菌素作為預防藥物(並攜帶防具)，投放對象為醫護人員或與確診者可能接觸確診者的家庭成員，則施以伊維菌素的參與者比單純只有護具的參與者發病率低

However, the study provided no data on the characteristics of the study
participants, types of exposures, or how endpoints were defined.24
不過這項研究並沒有提供參與者的統計資料、接觸確診者的方式與實驗終點的定義

Finally, in a small case-control study in SARS-CoV-2-exposed health care
workers, 186 participants who became infected were matched with 186
uninfected controls.
最後在一項小型病例對照研究中，研究與確診者接觸的醫護人員，186位參與者中，感染者與未感染者比對

Of those who received ivermectin after exposure to SARS-CoV-2, 38 were in theinfected group and 77 were in the uninfected group, which led the
investigators to conclude that ivermectin reduced the incidence of SARS-CoV-2infection.25
有使用伊維菌素的參與者，在接觸確診病患後，38人感染，77人未感染，因此此項研究結論伊維菌素可以減少新冠感染

Additional studies of ivermectin for SARS-CoV-2 are ongoing. Please see
ClinicalTrials.gov for the latest information.
更多的伊維菌素治療新冠的研究還在進行，可以至ClinicalTrials.gov調查更多資訊

更多伊維菌素的臨床試驗結果
(目前71項研究)
https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=ivermectin&cntry=&state=&city=&dist=&Search=Search

--

※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 123.194.193.193 (臺灣)